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ABSTRACT
Deregulated iron metabolism underlies the pathogenesis of many human cancers. 
Recently, low expression of ferroportin, which is the only identified non-heme iron 
exporter, has been associated with significantly reduced overall survival in multiple 
myeloma (MM); however, the altered iron metabolism in MM biology remains unclear. 
In this study we demonstrated, by live cell imaging, that MM cells have increased 
intracellular iron levels as compared with normal cells. In experiments to test the 
effect of iron chelation on the growth of MM cells, we found that deferasirox (DFX), 
an oral iron chelator used to treat iron overload in clinical practice, inhibits MM cell 
growth both in vivo and in vitro. Mechanistically, DFX was found to induce apoptosis 
of MM cells via the inhibition of proline-rich tyrosine kinase 2 (Pyk2), which is known 
to promote tumor growth in MM. Inhibition of Pyk2 is caused by the suppression of 
reactive oxygen species, and leads to downregulation of the Wnt/β-catenin signaling 
pathway. Taken together, our findings indicate that high levels of intracellular iron, 
which might be due to low ferroportin expression, play a role in MM pathophysiology. 
Therefore, DFX may provide a therapeutic option for MM that is driven by deregulated 
iron homeostasis and/or Pyk2/Wnt signaling.
INTRODUCTION
Iron is essential for many fundamental cellular 
functions, including proliferation and DNA synthesis 
[1]. Accumulating evidence suggests that abnormal iron 
metabolism plays an important role in carcinogenesis and 
in the progression of many tumors [2]. In cancer cells, 
the demand for iron increases in response to sustained, 
accelerated cell proliferation and DNA synthesis [3].
Multiple myeloma (MM) is characterized by clonal 
proliferation of long-lived plasma cells within the bone 
marrow. Despite recent advances in its treatment, MM 
remains an incurable disease, underlining the continuing 
need to explore its molecular characteristics [4]. Recently, 
two independent groups reported that serum ferritin, 
which is used as a marker for iron overload, can be a 
negative prognostic indicator in MM [5, 6]. However, 
the mechanisms underlying this effect have not been 
clarified, and the significance of iron metabolism in MM 
cells remains unclear. Ferroportin has also been shown 
to have a role in MM progression [7]. This cell-surface 
transmembrane protein is the only non-heme iron exporter 
identified in mammalian cells, and is a pivotal protein of 
iron homeostasis [8]. Reduced expression of ferroportin 
can lead to intracellular iron overload.
We previously reported that excess iron is a feature 
of myelodysplastic syndrome (MDS) and hepatocellular 
carcinoma pathogenesis [9, 10]. Moreover, we found 
that iron chelation with deferasirox (DFX) suppresses 
leukemic transformation in MDS patients, and long-term 
phlebotomy and low iron diet therapy lower the risk of 
hepatocarcinogenesis in patients with chronic hepatitis 
C. Remarkably, iron chelation therapy has been shown 
to suppress cancer cell growth and is considered to be a 
promising cancer treatment [11]. Several mechanisms for 
the cytotoxic effects of iron chelation therapy have been 
reported; however, its action might depend on both the cell 
type and the iron chelation agent [12-14].
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Proline-rich tyrosine kinase 2 (Pyk2) is a member 
of the focal adhesion kinase (FAK) family. It is a non-
receptor protein kinase that shares a similar central domain 
with FAK, showing 60% sequence identity. In addition, 
Pyk2 has a conserved arrangement of proline-rich regions 
and tyrosine phosphorylation sites [15]. Pyk2 plays a 
crucial role in cell proliferation, migration and invasion in 
several cancers [16]. Specifically, it has been implicated in 
the progression of MM and in micro-environment-specific 
MM cell survival [17, 18]. Hence, it is an attractive target 
for MM therapeutics.
In the present study, we observed that reduced 
ferroportin mRNA levels might lead to increased 
intracellular iron concentrations in MM cells. These 
observations prompted us to investigate the effects of iron 
chelation with DFX on MM. Both in vitro and in vivo, 
studies demonstrated that DFX induces apoptosis via the 
inhibition of Pyk2/β-catenin signaling in MM. Overall, our 
findings reveal that dysregulation of iron metabolism is a 
characteristic of MM and provide a strong rationale for using 
DFX as a therapeutic Pyk2/β-catenin inhibitor to treat MM.
RESULTS
Expression of ferroportin correlates with clinical 
outcomes
We previously demonstrated that an excess of 
intracellular iron contributes to the pathogenesis of MDS 
and hepatocellular carcinoma [9, 10]. To explore the 
hypothesis that iron overload might be also associated 
with MM pathogenesis, we initially analyzed the 
prognostic relevance of genes related to iron metabolism 
(Supplementary Tables S1 and S2) utilizing a data set in 
the public domain containing microarray profiles and MM 
patient outcomes. As Gu et al. [7] have shown, transcript 
levels of ferroportin are correlated with event-free survival 
(EFS) and overall survival (OS) in this data set, with a 
statistically significant negative correlation between 
ferroportin levels and EFS or OS (Supplementary Figure 
S1A, S1B). We therefore evaluated ferroportin mRNA 
expression in MM cell lines and primary MM cells. 
Quantitative reverse transcription (qRT)-PCR studies 
showed lower ferroportin mRNA expression in both MM 
cell lines and primary MM cells as compared with control 
cells (Figure 1A, 1B).
We also measured ferroportin transcript levels in 
other hematological malignancies, including leukemia 
and lymphoma. ferroportin mRNA expression was lower 
in B cell malignant cells than in leukemic cells or normal 
peripheral blood mononuclear cells (PBMCs) from healthy 
volunteers (Supplementary Figure S2).
Increased intracellular iron in MM cells
We considered that low expression of ferroportin 
might result in an increase in intracellular iron. To examine 
intracellular iron levels in MM cell lines, we determined 
the cellular iron content using FeRhoNox-1 staining [19]. 
Live cell imaging showed that cellular iron levels were 
apparently higher in MM cell lines than in PBMCs from 
healthy volunteers (Figure 1C). Together with another 
study [7], our data suggested that excess intracellular iron 
might contribute to MM pathogenesis.
Inhibition of MM cell proliferation by DFX
Our observations suggested that iron chelation might 
be an effective therapeutic intervention against MM. To 
examine whether DFX, an oral, long-acting iron chelator 
that is approved for iron overload, might be effective in 
MM, we tested its influence on the proliferation of MM 
cell lines using WST-1 assays. DFX significantly reduced 
the proliferation of MM cell lines, with IC50 values ranging 
from 3.2 to 47.9 μM (Figure 2A, 2B).
To assess the threshold level of intracellular iron 
for predicting DFX-induced cytotoxicity, the correlation 
between intracellular iron content and the IC50 for DFX 
was investigated in four MM cell lines. As shown in 
Figure 2B, a significant correlation was observed between 
the FeRhoNox-1-positive area and the IC50 of DFX (rs = 
-0.74, P = 0.004). Next, because bone marrow stromal 
cells (BMSCs) promote MM cell survival and induce drug 
resistance in MM cells, we tested the effect of BMSCs on 
the sensitivity of MM cells to DFX treatment. As shown 
in Figure 2D, DFX overcame the survival advantage 
conferred by the bone marrow microenvironment.
DFX induces apoptosis in human MM cells
To elucidate the cytotoxic mechanism of DFX on 
MM cells, we examined proteins involved programmed 
cell death by immunoblotting and performed flow 
cytometry analysis. We observed increased proteolytic 
cleavage of Caspase 9, Caspase 3, and PARP, but not 
Caspase 8 (data not shown) in all MM cell lines (Figure 
3A), indicating cell apoptosis. Treatment with the pan-
Caspase inhibitor Z-VAD significantly inhibited DFX-
induced apoptosis (Supplementary Figure S3). These 
results indicated that the cytotoxicity triggered by DFX is 
mediated, at least in part, via caspase-dependent (intrinsic) 
apoptosis.
As shown in Figure 3B, Annexin V/7-AAD staining 
showed a markedly higher percentage of apoptosis among 
MM1S and RPMI8226 cells (Figure 3B). A previous study 
has shown that DFX induces autophagy in MM cells [20]. 
In the present study, however, autophagic cell death was not 
indicated by immunoblotting of LC3A/B (data not shown).
To assess the contribution of iron chelation by 
DFX to cytotoxicity, we investigated whether iron 
supplementation might affect apoptosis. Pretreatment 
of MM cells with ferric chloride (FeCl3, 100 μM) in 
combination with DFX prevented DFX-induced apoptosis, 
as evaluated by flow cytometry (Figure 3B). These 
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observations strongly indicate that DFX-induced apoptosis 
depends on iron chelation by DFX. Furthermore, DFX-
induced apoptosis was detected in MM cell lines and 
primary MM cells (#3) under co-culture systems with 
BMSCs (Figure 3C).
DFX inhibits phosphorylation of Pyk2
To clarify the mechanisms of DFX-induced 
apoptosis in MM, we analyzed components of the 
phosphoinositide 3-kinase (PI3K)/Akt signaling pathway 
by PCR array (Qiagen, Hilden, Germany), because this 
pathway plays a crucial role in MM pathogenesis [21]. 
Unexpectedly, as shown in Supplementary Figure S4, 
FAK transcript expression was substantially suppressed 
after DFX treatment in both MM1S and RPMI8226 
cells. Expression of FAK protein was therefore tested 
by immunoblotting in a panel of MM cells. However, 
no expression of FAK protein was observed in three of 
the four cell lines (Figure 4A), indicating that FAK is not 
associated with DFX-induced apoptosis.
Next, we investigated Pyk2, which is a member 
of the FAK family and shares 48% amino acid sequence 
identify with FAK. Pyk2 was expressed differentially in 
the four different MM cell lines (Figure 4B). Consistent 
with a previous report [17], basal Pyk2 expression 
was relatively low in U266 cells. Consequently, we 
assessed Pyk2 activation after treatment with DFX. 
DFX significantly reduced the level of phosphorylated 
Pyk2(Tyr402), indicating in a loss of Pyk2 activity 
(Figure 4B). There were no substantial differences in 
total Pyk2 levels. In addition, we assessed the janus 
Figure 1: Decreased ferroportin expression and intracellular iron accumulation in MM cells. A, B. Expression of 
ferroportin mRNA in MM cell lines (A) and in CD138+ cells from MM patients (B) evaluated by qRT-PCR. Data are the mean of triplicate 
measurements. Error bars represent the SD. C. Intracellular iron content was monitored by live cell microscopy. Intracellular Fe2+ was 
stained by a FeRhoNox-1 probe. Scale bars, 10 μM.
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kinases Jak1, Jak2 and Jak3, because these molecules 
are also relevant in MM pathogenesis [22]. As shown 
Supplementary Figure S5, Jak1, Jak2 and Jak3 transcript 
levels were not suppressed by DFX treatment.
Recently, it was reported that reactive oxygen 
species (ROS) induce phosphorylation of Pyk2 in acute 
monocytic leukemia cells [23]. Furthermore, we have 
previously shown that DFX can inhibit ROS production 
in MDS [9]. These two observations prompted us to 
analyze changes in ROS production in DFX-treated MM 
cells. Flow cytometric analysis using CellROX deep red 
probes revealed that DFX significantly suppressed ROS 
production in MM cells (Figure 4C). Taken together, these 
data suggest that DFX exerts anti-myeloma activities by 
inhibiting Pyk2 phosphorylation, following a decrease in 
ROS production.
Pyk2 inhibition by DFX suppresses the Wnt/β-
catenin signaling pathway
Next, we analyzed Pyk2 downstream target 
molecules in order to clarify the mechanism of DFX-
induced apoptosis in MM. It has been shown that 
inhibition of Pyk2 promotes β-catenin degradation via 
the activation of GSK-3β [17]. In MM cells, as expected, 
β-catenin protein levels were reduced by DFX treatment, 
accompanied by decreased levels of phosphorylated-
GSK-3β (inactive form), resulting in the degradation of 
β-catenin (Figure 5A).
Wnt signaling activities were also examined by 
qRT-PCR and immunoblotting. Treatment with DFX 
reduced the mRNA levels of Axin2 and c-Myc, which 
are target genes of Wnt; in particular, Axin2 is a robust 
Figure 2: Iron chelation with DFX inhibits the proliferation of cultured MM cells. A, C. MM cell lines (A) and primary 
MM cells isolated from two MM patients (C) were cultured with DFX (0-50 μM) for 48 hours. Cell proliferation was assessed in triplicate 
cultures by WST-1 assays. Data are the mean ± SD of triplicate measurements (n = 3; P < 0.05 for all cell lines). IC50 values are for growth 
inhibition by DFX. (B) Correlation between the FeRhoNox-1-positive area and IC50 values for DFX in four MM cell lines. The relationship 
was tested by two-tailed Spearman correlation (rs). D. RPMI8226 cells were cultured for 48 hours in HS-5-coated, primary BMSC-coated, 
or uncoated wells with DFX at its IC50 concentration. Primary BMSCs were derived from two MM patients (#1, #2). Cell proliferation was 
assessed by BrdU assays. Data are the mean of triplicate measurements. Error bars represent the SD. * P < 0.01.
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and specific Wnt target gene (Figure 5B). In addition, 
immunoblotting showed that c-Myc and cyclin D1, which 
function downstream of β-catenin in the Wnt pathway, 
were significantly decreased by DFX treatment (Figure 
5C). Collectively, these results supported the hypothesis 
that DFX inhibits activation of Wnt/β-catenin signaling.
Lastly, to pinpoint the function of Pyk2 in MM cells, 
we performed in vitro Pyk2 loss-of-function analysis. 
Similar to DFX treatment, Pyk2 knockdown with siRNA 
in MM cells led to a decrease in β-catenin and c-Myc 
protein levels (Figure 5D).
Anti-tumor activity of DFX in mouse xenograft 
models
To test the therapeutic potential of DFX, we 
evaluated its ability to suppress tumor growth in vivo 
by using the subcutaneous RPMI8226 murine xenograft 
Figure 3: DFX induces apoptosis in MM cells. A. Four MM cell lines were treated with DFX for 0, 24 and 48 hours. Whole-cell 
lysates were subjected to immunoblotting using anti-Caspase 9, anti-Caspase 3, anti-PARP, and anti-β-actin antibodies. FL; full length, 
CL; cleaved form. B. MM1S and RPMI8226 cells were pre-incubated with or without 100 mM FeCl3 for 2 hours. Cells were washed three 
times with phosphate-buffered saline and then treated with the IC50 concentration of DFX for 48 hours. Apoptotic cells were analyzed 
by flow cytometry using Annexin V/7-AAD staining. Data are the mean of triplicate measurements. Error bars represent the SD. * P < 
0.01. C. MM1S, RPMI8226 and primary MM (#3) cells were cultured for 48 hours in BMSC (HS-5)-coated or uncoated wells with DFX. 
Apoptotic cells were analyzed by flow cytometry using Annexin V/7-AAD staining. Data are the mean of triplicate measurements. Error 
bars represent the SD. * P < 0.01.
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Figure 4: DFX exerts anti-myeloma activity by inhibition of Pyk2 phosphorylation accompanied by reduced production 
of ROS. A. Expression of FAK and Pyk2 in MM cell lines was evaluated by immunoblotting. B. Immunoblot of total protein extracts 
obtained from MM1S, RPMI8226 and primary MM cells (#4) treated with or without DFX for 24 hours. The active form of Pyk2 was 
analyzed by using an anti-p-Pyk2 antibody. C. MM1S and RPMI8226 cells were cultured for 2 hours with DFX. ROS production was 
analyzed by flow cytometry using CellRox deep Red staining. Data are the mean of triplicate measurements. Error bars represent the SD. 
* P < 0.01.
Figure 5: DFX treatment and Pyk2 silencing lead to suppression of the Wnt/β-catenin signaling pathway. A. MM1S, 
RPMI8226 and primary MM cells were treated with DFX for 24 hours, and subjected to immunoblot analysis for total GSK3β and β-catenin 
protein. The inactive form of GSK3β was analyzed by using an anti-p-GSK3β antibody. B. qRT-PCR validation of pivotal Wnt target genes 
in MM1S and RPMI8226 cells treated with DFX. Data are the mean of triplicate measurements. Error bars represent the SD. * P < 0.01. 
C. Immunoblot analysis of c-Myc and cyclin D1 levels in DFX-treated MM cells. D. Immunoblot analysis of β-catenin and c-Myc protein 
expression in cells transfected with Pyk2 siRNA.
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model of human MM. After DFX treatment, the MM 
tumor burden was significantly lower in the DFX group 
than in the vehicle group (Figure 6A). DFX treatment for 
35 days was well tolerated, without causing significant 
body weight loss (Figure 6B). We also detected an 
increase in apoptotic tumor cells in mice treated with 
DFX as compared with vehicle-treated mice, as evaluated 
by Cleaved-PARP staining and immunoblotting (Figure 
6C, 6D). No histologic changes in normal tissues 
were observed in the treatment group upon necropsy 
(Supplementary Figure S6).
To evaluate the inhibition of target proteins by DFX 
in vivo, we performed immunoblotting analysis of the 
tumors. Consistent with the in vitro results, significantly 
lower levels of phosphorylated Pyk2 and β-catenin protein 
were observed in tumors obtained from DFX-treated mice 
than in those obtained from vehicle-treated mice (Figure 
6D). Taken together, these data demonstrate the potent in 
vivo anti-MM activity of DFX, providing the framework 
for clinical application of DFX in this disease.
To test whether the anti-proliferative effect of DFX 
might synergize with other agents commonly used to treat 
MM, we also conducted a study of combination treatment. 
Notably, the cytotoxic effects of bortezomib on MM 
cells were enhanced by DFX treatment (Supplementary 
Figure S7), suggesting the potential clinical utility of this 
combination therapy.
DISCUSSION
In the current study, our data demonstrate that 
ferroportin plays an important role in the clinical outcome 
of MM. In the gene expression profiling of MM patients, 
we observed a reduction in ferroportin mRNA, which 
was associated with a poor prognosis. Low transcript 
levels of ferroportin were observed both in MM cell 
Figure 6: DFX inhibits tumor growth in a mouse xenograft model of MM. A. Tumor volumes were calculated from caliper 
measurements. Data represent the mean ± SD (n=5). * P < 0.05. B. The body weight of mice treated with DFX or vehicle was monitored 
every day. Data are the mean ± SD. NS, not significant. C. Histologic analysis of sections stained with hematoxylin and eosin (H&E) and 
Cleaved-PARP antibody from DFX-treated mice. Scale bars, 50 μM. D. Tumors harvested from DFX-treated and untreated mice were 
subjected to immunoblot analysis for PARP, Pyk2, p-Pyk2 and β-catenin protein.
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lines and in primary MM cells, which led us to evaluate 
intracellular iron in MM cells, because reduced expression 
of ferroportin might increase intracellular iron content [1, 
24]. Previous studies also support this possibility, because 
MM cells have been shown to be able to uptake and 
store iron as well as normal plasma cells [25, 26]. Gu et 
al. [7] reported recently that down-regulated ferroportin 
correlated negatively with OS, as shown in the present 
study, and that the increase in intracellular iron content 
caused by reduced expression of ferroportin accelerated 
MM cell growth and bone absorption. However, iron 
homeostasis and intracellular iron accumulation in human 
MM cells has not yet been studied extensively. We are 
the first to demonstrate high concentrations of intracellular 
iron (Fe2+) by live cell imaging using the FeRhoNox-1 
stain, providing insight into the role of intracellular iron 
overload in MM pathogenesis.
We next evaluated the effect of iron chelation as 
a treatment for MM, because excess iron can accelerate 
tumor cell proliferation. To date, DFX has been reported 
to have anti-tumor activity in several types of cancer [14, 
27-29]. Indeed, in vitro results reported by Pullarkat et al. 
[20] during preparation of this manuscript indicated that 
DFX had a cytotoxic effect against MM cells. Consistent 
with this, our data revealed that DFX effectively induces 
apoptosis of MM tumor cells both in vivo and in vitro. Of 
note, intracellular iron content might predict whether MM 
cells will show DFX cytotoxicity.
Our data suggested that DFX suppressed ROS 
production and led to Pyk2 inhibition. Consequently, 
DFX-triggered apoptosis was initiated. In support 
of our findings, recent studies have shown that Pyk2 
inhibitors might offer a novel therapeutic intervention 
for MM [17, 18]. Pyk2 inhibition results in suppression 
of Wnt signaling through the acceleration of β-catenin 
degradation caused by GSK3β activation [17]. Aberrant 
activation of the Wnt pathway plays a significant role in 
MM progression and maintenance [30-32]. Interestingly, 
iron chelators have been shown to act as Wnt inhibitors 
and to suppress tumor cell growth [33, 34]; however, 
the mechanism underlying the decreased expression of 
β-catenin protein caused by DFX has not been clearly 
defined. Notably, our findings provide the first description 
of the iron chelator DFX inhibiting MM cell growth via 
the inhibition of ROS/Pyk2/β-catenin.
We also demonstrated for the first time the efficacy 
of DFX in suppressing tumor growth in vivo by using a 
well-established murine xenograft model of MM [35]. 
Mice were treated daily with DFX at 20 mg/kg, a dosage 
that is clinically appropriate because it is the starting 
dose for patients with transfusional iron overload [36]. 
Therefore, our observations might be quickly translated 
into a clinical trial for MM patients, because DFX is 
well tolerated and is already approved and used widely 
to treat iron overload patients. Notably, we showed 
that administration of DFX also enhanced bortezomib 
cytotoxicity against MM cells. Bortezomib has been 
shown to markedly improve the EFS and OS for MM 
patients. However, both resistance to and adverse effects 
of bortezomib are emerging as therapeutic problems. 
Combination approaches have been proposed to prevent 
and/or overcome bortezomib resistance [37]. Accordingly, 
a combination therapy using DFX and bortezomib might 
provide a new strategy to enhance bortezomib cytotoxicity 
and overcome resistance to this MM therapeutic.
In practical terms, nephrotoxicity is acknowledged 
as the most common adverse effect of DFX. On the one 
hand, DFX nephrotoxicity, defined as an increase in 
serum creatinine level, has been observed in 18%–22% 
of DFX-treated patients [38]. Although the molecular 
mechanism underlying the nephrotoxicity remains unclear, 
it is characterized by proximal tubular dysfunction 
and related to reversible tubular cell injury. When this 
toxicity occurs, adjustment of the DFX dose should be 
considered. On the other hand, renal impairment known as 
“myeloma kidney” is a common complication of patients 
with MM, and 79% of patients have been found to have 
serum creatinine levels lower than 2 mg/dL at the time of 
diagnosis [39]. Bortezomib-based therapies were reported 
to bring a significant improvement of renal function 
(major renal response) to 77% of newly diagnosed MM 
patients [40]. Although the clinical administration of DFX 
to MM patients might pose some difficulties, DFX can 
be administered to MM patients with or without dose-
adjustment protocols during the course of the disease.
In conclusion, this study has demonstrated that 
low expression of ferroportin is associated with a poor 
prognosis in MM and might be related to increased levels 
of intracellular iron that contribute to MM pathogenesis. 
Our results suggest the potential clinical application of 
DFX to the treatment of iron-overloaded and/or Pyk2/β-
catenin-driven MM.
MATERIALS AND METHODS
Gene expression and survival analysis
Expression levels of iron regulatory genes 
(Supplementary Tables S1 and S2) were evaluated by 
using the publicly accessible MAQC-II Project MM data 
set (GSE24080) from the Gene Expression Omnibus. The 
correlation between ferroportin mRNA levels and clinical 
outcome was investigated by evaluating expression levels 
stratified by the median value. In total, 554 patients were 
categorized as having high or low levels of ferroportin, 
and Kaplan-Meier survival analysis comparing the two 
groups was performed.
Reagents and human cell lines
DFX was obtained from Santa Cruz Biotechnology 
(Dallas, TX). Stock solutions were generated by 
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dissolving the lyophilized powder in 100% DMSO at 100 
mM. MM1S, RPMI8226 and U266 cell lines were kindly 
provided by Dr Ruben D. Carrasco (Dana-Farber Cancer 
Institute, Harvard Medical School, Boston, MA). Delta-47 
and HS-5 cells were purchased from ATCC (Manassas, 
VA). All MM cell lines were cultured in RPMI 1640 
(Sigma-Aldrich, St. Louis, MO) containing 10% fetal 
bovine serum (FBS), 2 μM l-glutamine and 1% penicillin-
streptomycin. HS-5 cells were cultured in DMEM (Sigma-
Aldrich) supplemented with 10% FBS, 2 μM l-glutamine 
and 1% penicillin-streptomycin.
Patient specimens
PBMCs were obtained from blood samples from 
healthy volunteers by using Histopaque-1077 (Sigma-
Aldrich) gradient fractionation. Bone marrow specimens 
were obtained from patients with MM after obtaining 
Sapporo Medical University School of Medicine Review 
Board approval and informed consent, and were obtained 
in compliance with the Declaration of Helsinki. Primary 
CD138+ plasma cells were purified by positive selection with 
anti-CD138 magnetic-activated cell separation microbeads 
(Miltenyi Biotec, Auburn, CA) as described [41]. According 
to a previous report, primary BMSCs were established from 
CD138– bone marrow mononuclear cells [35].
RNA extraction and quantitative reverse 
transcription-PCR
RNA was extracted with TRIzol Reagent (Life 
Technologies, Carlsbad, CA) in accordance with the 
manufacturer’s protocol. Total RNA (1 μg) was reverse-
transcribed by using a SuperScript VILO cDNA synthesis 
kit (Life Technologies), and qRT-PCR was performed 
with an Applied Biosystems 7300 Real-time PCR system 
(Applied Biosystems, Foster City, CA). Analysis of target 
genes was conducted in quadruplicate using the POWER 
SYBR Green Master Mix (Life Technologies) as previously 
described [30]. Transcripts levels were normalized to 
β-actin expression. The experiments were repeated 
three times. The following PCR primers were designed: 
5’-CTACTTGGGGAGATCGGATGT-3’ and 5’-CTGGGC 
CACTTTAAGTCTAGC-3’ for ferroportin; 5’-AGCCA 
AAGCGATCTACAAAAGG-3’ and 5’-GGTAGGCAT 
TTTCCTCCATCAC-3’ for Axin2; 5’-TTTTTCGGGT 
AGTGGAAAACC-3’ and 5’-GCAGTAGAAATACGGC 
TGCAC-3’ for c-Myc; 5’-GGCATCCTCACCCTGA 
AGTA-3’ and 5’-GAAGGTGTGGTGCCAGATTT-3’ for 
β-actin.
Fe2+ fluorescent stain
For Fe2+ detection, cells were stained for 1 hour at 
37 ºC with 5 μM FeRhoNox-1 (Goryo Chemical, Sapporo, 
Japan) and 1 μg/ml hoechst33342 (Life Technologies). 
After staining, cells were washed and observed by live 
cell imaging using a Biozero BZ-8000 fluorescence 
microscope (KEYENCE Laboratories, Osaka, Japan).
Growth inhibition and apoptosis assays
The inhibitory effect of DFX on MM cell line 
growth was assessed by WST-1 assay, as described 
previously [42]. To analyze the proliferation of MM 
cells with or without BMSCs, the rate of DNA synthesis 
was determined by BrdU assay (BrdU cell proliferation 
assay reagent, Cell Signaling Technology, Danvers, MA). 
Apoptosis was evaluated by PARP immunoblotting and 
quantified by using an Annexin V/7-AAD staining kit in 
accordance with the manufacturer’s instructions (Annexin 
V PE Apoptosis Detection Kit I, BD Biosciences, San 
Jose, CA), followed by analysis on a BD FACS Canto II 
instrument using FACSDiva (BD Biosciences) [43].
Inhibition of Pyk2 expression by small-
interfering RNA (siRNA)
A non-silencing control and siRNA targeting Pyk2 
were purchased from Thermo Scientific (Waltham, MA) 
and transfected into cell lines by electroporation using 
Nucleofector, according to a previous report [18].
Immunoblotting
MM cells were cultured with or without stimuli; 
the cells were then harvested, washed, lysed, and 
stained by using primary antibodies to the following 
proteins: PARP (#9542), FAK (#3285), Pyk2 (#3292), 
Phospho-Pyk2 (Tyr402) (#3291), GSK-3-α/β (#5676), 
p-GSK-3-α/β (Ser21/Ser9) (#9331), cyclin D1 (#2978) 
(all Cell Signaling Technology); c-myc (OP10L; EMD 
Biosciences, San Diego, CA); Actin-HRP (sc-1615; (Santa 
Cruz Biotechnology); β-catenin (CAT5-H10; Invitrogen 
Corporation, Carlsbad, CA). Standard chemiluminescence 
was used to evaluate protein expression.
ROS measurement
For quantification of ROS, cells were stained for 30 
min at 37 ºC with 5 μM CellROX Deep Red (Invitrogen). 
After staining, cells were washed and suspended in 
PBS. For quantification of intracellular ROS, cells 
were analyzed by a BD FACS Canto II instrument (BD 
Biosciences, Tokyo, Japan).
Murine xenograft model of human MM
NOD/Shi-scid IL-2γnul (NOG) mice (8 weeks old, 
female) were purchased from the Central Institute for 
Experimental Animals (Kawasaki, Japan). All animal 
studies were conducted according to protocols approved 
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by the Animal Ethics Committee of the Sapporo Medical 
University School of Medicine. Mice were inoculated 
subcutaneously in the left flank with 3 x 107 RPMI8226 
cells in 100 μL of RPMI1640 with 100 μL of Matrigel 
(Corning, Corning, NY). When the tumor volume 
reached 100 mm3, mice were assigned to two groups that 
received either vehicle alone or DFX (n = 5 per group). 
The DFX group received DFX suspended in vehicle 
[30% 1,2-propanediol/70% sterile 0.9% sodium chloride 
solution (v/v)], which was administered by oral gavage 
every day at 20 mg/kg [29]. Control mice were treated 
in the same way with vehicle only. Caliper measurements 
of the longest perpendicular tumor diameters were 
performed on alternate days to estimate the tumor volume 
via the following formula: length × width2 × 0.5. Complete 
necropsies were performed for each experimental animal. 
Tissues were subjected to hematoxylin and eosin staining, 
and immunohistochemical analysis with anti-Cleaved 
PARP antibody (Cell Signaling Technology).
Statistical analysis
The significance of differences between groups 
was determined by Student t test. Statistical significance 
was defined at a P value of less than 0.05. Kaplan-Meier 
survival analysis was carried out by using GraphPad Prism 
analysis software version 6.0a (GraphPad Software, San 
Diego, CA).
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